Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15455
UPID:
TLR3_HUMAN
Alternative names:
-
Alternative UPACC:
O15455; B2RAI7; B7Z7K0; E6Y0F0; E6Y0F1; E9PGH4; Q4VAL2; Q504W0
Background:
Toll-like receptor 3 (TLR3) plays a pivotal role in the immune system, acting as a sentinel against viral pathogens. It recognizes double-stranded RNA, a molecular signature of viral infection, triggering a cascade that includes NF-kappa-B activation and cytokine secretion, culminating in an effective immune response.
Therapeutic significance:
Given its crucial role in defending against a range of viral infections, including those leading to Immunodeficiency 83, TLR3 presents a promising target for therapeutic intervention. Enhancing TLR3 function could bolster resistance to severe viral diseases, offering a pathway to novel treatments.